Abstract Numerous novel and effective therapeutic agents and clinical trials addressing castration-resistant prostate cancer (CRPC) were reported during the 2023 American Society of Clinical Oncology-Genitourinary (ASCO-GU) Cancers Symposium. Notably. radionuclide drug conjugates (RDC). specifically 177Lu/111In-J591 and 225Ac-J591. https://megavitamines.shop/product-category/health-and-wellbeing/